Skip to content
10-K

Annual Report

Acrivon Therapeutics, Inc. ACRV

0001193125-26-115123

← back to feed
Filed
Mar 19, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 16, 2026 38.74M sh
Shares Diluted FY 2025 · Dec 31, 2025 38.51M sh
Shares Diluted FY 2025 · Dec 31, 2024 33.79M sh
Capex FY 2025 · Dec 31, 2025 $1.67M
Capex FY 2025 · Dec 31, 2024 $2.77M
Operating Cash Flow FY 2025 · Dec 31, 2025 −$63.67M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$65.67M
Short Term Investments FY 2025 · Dec 31, 2025 $77.08M
Short Term Investments FY 2025 · Dec 31, 2024 $139.66M
Cash And Equivalents FY 2025 · Dec 31, 2025 $41.5M
Cash And Equivalents FY 2025 · Dec 31, 2024 $39.82M
Stockholders Equity FY 2025 · Dec 31, 2025 $112.52M
Stockholders Equity FY 2025 · Dec 31, 2024 $176.79M
Stockholders Equity FY 2025 · Dec 31, 2023 $121.2M
Current Liabilities FY 2025 · Dec 31, 2025 $15.66M
Current Liabilities FY 2025 · Dec 31, 2024 $17.21M
Total Liabilities FY 2025 · Dec 31, 2025 $17.2M
Total Liabilities FY 2025 · Dec 31, 2024 $19.8M
Current Assets FY 2025 · Dec 31, 2025 $120.45M
Current Assets FY 2025 · Dec 31, 2024 $181.63M
Total Assets FY 2025 · Dec 31, 2025 $129.72M
Total Assets FY 2025 · Dec 31, 2024 $196.59M
Eps Diluted FY 2025 · Dec 31, 2025 −$2.02
Eps Diluted FY 2025 · Dec 31, 2024 −$2.38
Eps Basic FY 2025 · Dec 31, 2025 −$2.02
Eps Basic FY 2025 · Dec 31, 2024 −$2.38
Sga Expense FY 2025 · Dec 31, 2025 $24.12M
Sga Expense FY 2025 · Dec 31, 2024 $25.21M
Rd Expense FY 2025 · Dec 31, 2025 $59.99M
Rd Expense FY 2025 · Dec 31, 2024 $63.99M
Net Income FY 2025 · Dec 31, 2025 −$77.91M
Net Income FY 2025 · Dec 31, 2024 −$80.56M
Operating Income FY 2025 · Dec 31, 2025 −$84.11M
Operating Income FY 2025 · Dec 31, 2024 −$89.2M